Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs. The company’s portfolio centers on treatments for sleep-wake disorders and related neurological conditions, with a strong emphasis on patients whose options remain limited. Its marketed therapy, WAKIX, is designed for the treatment of excessive daytime sleepiness in adults with narcolepsy, reflecting the company’s focus on specialized neuroscience care. Harmony Biosciences also advances research programs in adjacent rare neurological and endocrine disorders, combining commercial operations with clinical development capabilities. Headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences plays a focused role in the biopharmaceutical market by addressing niche patient populations through targeted, science-driven therapies.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Jeffrey M. Dayno M.D.

Employees

293

Headquarters

Plymouth Meeting, PA, United States

Website

www.harmonybiosciences.com